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How whole-organ transplantation carne to be a clinical 
discipline has been told elsewhere by many of the persons 
directly involved (1). The events through 1959 was dominated by 
the kidney (2). However, the extrarenal vacuum rapidly filled in 
the late 1950s with the development in several laboratories of 
canine transplant models with which to study all of the intra-
abdominal and thoracic organs. Pig and rodent models came later. 
Each organ-defined specialty has had its historians, but in 
all such accounts the preoccupation has been with a succession of 
events rather than with the poorly understood biologic principles 
by which all organs can escape rejection. This conventional 
approach can be capsulized by noting the first successful 
allotransplantation of the kidney (3) I liver (4) I heart (5), lung 
(6), pancreas (7), intestine (8), multiple abdominal viscera (9) I 
and bone marrow (10 -12). Such milestones are important. 
However. our concern here will be with the steps by which organ 
:ransplantation 'lIas developed empirically without knowing how 
:his had been accomplished. and then the understanding that came 
later. Such generic information may be of use to 
anesthesiologists who care for all kinds of transplant 
recipients. 
THE IMMUNOLOGIC BARRIER 
By avoiding problems with rejection, the potential benefit 
of human whole organ replacement was unequivocally demonstrated 
with the identical twin transplantation performed in December 
1954, by Joseph E. Murray (Nobel Laureate, 1990). However, this 
achievement was symbolic only, showing with an identical twin 
organ what was already known to be possible with skin grafts. 
Seven years later, the Nobel Laureate (1960), Macfarland Burnet, 
wrote in the New England Journal of Medicine that " . much 
thought has been given to ways by which tissues or organs not 
genetically and antigenetically identical with the patient might 
be made to surv:.':e and function in the alien environment. On the 
whole, the present outlook is highly unfavorable to success . 
" (13) 
THE ONE-WAY PARADIGM 
Rejection 
:vhat ',-las ::-.e genetically determined barrler? .21.1 though 
details are obscure, ::here was little mystery after 1944 about 
the general meaning of transplant rejection, following its 
elucidation by ~edawar (co-Nobel Laureate with Burnet, 1960) as 
an immunologic e'Jent (14). This great contribution created the 
:ndelible image :hat a tissue (or organ) allograft was an island 
in 3. hostile reclpient sea (Figure 1A) . 
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Tolerance 
In contrast, why allografts or xenografts can escape from 
rejection with or without the aid of immunosuppression has been 
one of the most arcane subjects in biology ever since the 
description of acquired tolerance by Billingham, Brent, and 
Medawar (15,16) more than 4 decades ago. A simple explanation 
for the tolerance in their special model was at first beguiling. 
Immunocompetent adult spleen cells were injected in utero or 
perinatally into mice that had not yet evolved the immunologic 
equipment to ~eject them. The engrafted cells flourished, 
perpetuated themselves, and in effect endowed the recipient with 
the donor immune system. Thereafter, the chimeric mice failed to 
recognize donor strain skin or other tissues as alien. 
Tolerance in this second landmark contribution from 
:'ledawar's laboratory ·,."as explained as a switch in immunologic 
apparatus and ~as consistent with the definition of 
~ransplantaticn immunology in terms of a unidirectional immune 
reaction (a "one-way paradigm"). This view was strengthened by 
the studies of Main and Prehn (17) who demonstrated the same 
tolerance outcome as Billingham, Brent, and Medawar in irradiated 
,l.dul t ;nice, ·,."hose cytoablated hematolymphopoiet ic cells were 
~econstituted with bone marrow. Hundreds of subsequent tolerance 
induction experiments in animals, and eventually clinical bone 
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marrow transplantation seemingly depended upon a similar natural, 
or iatrogenically imposed, defenseless recipient state (Figure 
1B) . 
Graft Vs Host Disease (GVBD) 
The anticipated clinical application of this kind of 
tolerance induction was temporarily derailed in 1957 when it was 
realized that an immunologically active graft could turn the 
tables and reject the recipient (graft versus host disease 
[GVHD)) Billingham and Brent showed in their mouse model (18) 
and Simonsen in chickens (19) that this risk (also called runt 
disease) was roughly proportional to the extent of the major 
histocompatibility complex (MHC) barrier. Such disparities 
became measurable in humans after identification of the HLA 
antigens by Dausset (20) (Nobel Laureate, 1980), Terasaki, and 
others (21). The complication of GVHD in rodent (22) and large 
lnimal irradiation chimera models (23-26) forestalled for many 
:.:ears the clinlcal use of HLA mismatched bone marrow cells or 
other mature imrnunocytes, either for immunologic reconstitution 
:or purely hematologic purposes or as a means of facilitating 
~hole organ graft acceptance. 
Clinical Bone Marrow Transplantation 
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Nevertheless, a strategy for clinical bone marrow 
transplantation eventually was assembled directly from the rodent 
experiments, but with similar histocompatibility-imposed 
restrictions (23). After recipient cytoablation with total body 
irradiation (TEl) or cytotoxic drugs, stable chimerism could be 
induced in humans by the infusion of donor bone marrow if there 
was a good HLA match. Otherwise there was an intolerable 
incidence of GVHD. After successful engraftment, maintenance 
immunosuppression frequently was not needed, mimicking the kind 
of acquired immunologic tolerance originally described by 
Billingham, Brent, and Medawar (15,16), and then Main and Prehn 
(17). ~he eventual success of clinical bone marrow 
transplantation (10-12) was a straight line extension from these 
rodent models as Nobel Laureate Thomas (1990) has summarized 
(23) . 
Clinical Organ Transplantation 
With Total Body Irradiation --- The achievement of clinical 
bone marrow transplantation effectively detached from a 
scientific base the surgeons who by this time already had 
recorded many successful human whole organ transplantations 
.. mostly r~idneysF 'Jnder continuous immunosuppression - - - ' . ."ithout 
dependence on HLA matching or the complication of GVHD, and as 1: 
~urned ~utI without host preconditioning. Preconditioning with 
sublethal TBl was in fact used in the first successful renal 
allotransplantation described by Murray and Merrill et al in 1960 
(3). However, the kidney recipient, whose donor was his 
fraternal (dizygotic) twin brother, was not given bone marrow, 
already a significant departure from the Billingham-Brent-Medawar 
framework. The recipients own bone marrow recovered, and the 
transplanted kidney and patient survived for 20 years. Six 
additional examples of protracted kidney graft survival (> 1 
year) after recipient irradiation without marrow were recorded in 
Paris over the next 36 months (27,28). Five of the 6 donors were 
more distant than a fraternal twin and two were genetically 
unrelated (28) However, these were isolated successes in a sea 
of failures. 
Chemical Immunosuppression --- The frustration continued 
after the introduction for human renal transplantation of 6-
mercaptopurine (6-MP) and its analogue azathioprine by Murray et 
31 (29) Eollowlng extensive experimental studies, first with 
~odent skin transplantation (30,31) and then with canine kidney 
transplant models (29,32-34) The drugs originally had been 
developed as antileukemic agents by Elion and Hitchings (35) 
Nobel Laureates, 1988) and were first demonstrated to be 
~mmunosuppresslD:e by Schwart:: and Dameshek (36). .::.lthough the 
slxth patient ~reated by Murray with one or the other of these 
~yelotoxic drugs had function of a non-related renal allograft 
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for 17 months, the clinical results were poor at first (29,37), 
similar to those with TEl. 
The Double-Drug BreakthrQugh --- The tidal wave of whole 
organ cases began in earnest in 1962 when azathioprine was 
combined with prednisone (38). Now, a characteristic cycle was 
identified in which rejection could be reversed surprisingly 
easily with prednisone. More importantly, the need later on for 
maintenance immunosuppression frequently declined, and in 
occasional cases treatment could be stopped. The same sequence 
has been seen since with all other organs transplanted and with 
all of the immunosuppressive regimens (Figure 2). Agents 
introduced later were more potent and reliable in chaperoning the 
desired chain of events: antilymphocyte globulin (ALG) (39), 
cyclosporine (40), and FK 506 (41). Notwithstanding their 
diversity, all of the drugs seemed in a fundamentally similar way 
to have allowed something to change in the host, the graft or 
both. Sut what? 
Answers were not provided by the one-way paradigm of 
transplantation :mmunology that had gained ascendency nearly a 
half century ago. The ~alse conception of a unidirectional 
reactlon was never serlously challenged after it was seemingly 
supported by studies Wl t:h the one-way mixed l:;mphocyt:e reaction 
,MLR) :ntroduced in 1963 by Bach and Hirschorn (42) and Sain et 
31 (43). These In ~it~o technlques (so-called mlnitransp1ant 
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models) generated thousands of increasingly sophisticated 
cellular and ultimately molecular studies of unidirectional 
immunologic reactions. Ironically, the resulting plethora of new 
information resembled at times an exponentially expanding phone 
book filled with wrong numbers. Most seriously, the flawed 
context lured successive generations of investigators into the 
trap of believing that tolerance induction for whole organ 
recipients (the "holy grail") lay in variations on the HLA-
limiting strategy used for bone marrow transplantation, that 
included host preconditioning in preparation for a variety of 
donor leukocyte preparations. 
THE TWO-WAY PARADIGM 
Whole Organ Transplantation 
A plausible explanation did not emerge for the success of 
:he empirically developed whole organ transplantation procedures 
:mtll 1992. Then, it 'Nas discovered in a study of pioneer kidney 
~nd liver recipients who were still extant from the earliest 
clinical trials that donor leukocytes of bone marrow origin which 
eIre part of the structure of all complex grafts ("passenger 
leukocytes" [44,45J) had migrated from the organs and survived 
~biquitously in these patients for up to 30 years (46,47). Thus, 
)rgan allograft acceptance was associated with the cryptic 
sur':l':al including stem cells of a small fragment of 
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extramedullary donor marrow (depicted as a bone silhouette in 
Figure 1 C), which was assimilated into the overwhelmingly larger 
immunologic network of the host. The cell movement was in both 
directions, with small numbers of residual donor leukocytes 
(microchimerism) in both the graft and host. 
From this information, a revision of transplantation 
immunology was possible in which the immunologic confrontation 
following whole organ transplantation could be seen as 
bidirectional (GVH as well as HVG) and mutually cancelling 
(Figure 3), providing the 2 participants in the David/Goliath 
mismatch could survive the initial onslaught. In a clinical 
context, but not in several animal models, this survival requires 
an umbrella of :mmunosuppression that protects both cell 
populatlons equally (Figure 1 C). Current research is targeted 
to understanding the amplication device by which a small number 
of cells can so profoundly affect the immunologic vision of the 
·:ast army agalnst ·.vhich "i t is arrayed. .:;.1 though the chimeric 
leukocytes are multilineage (46-49), the antigen presenting 
dendritic cells of Steinman and Cohn (50,51) are thought to be 
critical because they can modify the expression of cell 
interaction, MHC, and adhesion molecules --- all of which 
determlne how antlgen signals are heeded by T cells (51)" 
Historical Enigmas - - - With the olo-way paradigm, ·:irtually 
~very previously unexplained experimental or clinical observation 
after whole organ transplantation became either transparent, or 
at least susceptible to experimental inquiry (46,47). It could 
be understood why organ grafts are inherently tolerogenic, why 
HLA matching is so poorly predictive of outcome, and why GVHD 
does not develop after the transplantation of immunologically 
active grafts such as the liver and intestine. 
With the two-way mutual cancellation implicit in this 
concept, the loss or blunting of an HLA matching effect is easy 
to understand. Nith each further level of histoincompatibility, 
the reciprocal effect is postulated to escalate both ways 
providing the process is chaperoned with an effective 
immunosuppressr:e umbrella (Figure 4). The consequent dwindling 
of the matching effect as donor-specific and recipient-specific 
nonreactivity evolves accounts for blind folding of the expected 
HLA effect. In addition to explaining why the HLA matching 
effect .:...s "blind folded", this bidirectional cancelling effect of 
~he 2 cell populations explains why GVHD does not develop after 
liver, .:...ntestinal, multivisceral, and heart-lung transplantation 
despite the heavy lymphoid content of those organs. 
Augmentation of Spontaneous Chimerism --- Historical efforts 
to give extra donor antigen in the form of bone marrow (52,53) or 
donor blood transfusions (54-56) had been hampered in design or 
executlon by the assumption that the infused cells would be 
jestroyed without recipient preconditioning, Justifiable anxiety 
about GVHD if host preconditioning was provided, and a lack of 
information about the appropriate timing of the infusions. The 
new information that chimerism is a naturally occurring event 
after whole organ transplantation (46,47) exposed a perioperative 
window of opportunity during which unaltered HLA incompatible 
bone marrow or donor specific blood transfusion was predicted to 
be safe without recipient preparation or deviation from the 
generic practices of immunosuppression for whole organ 
transplantation that had evolved over the years from the original 
azathioprine-prednisone formula (38). 
The validity of this strategy was verified recently in non-
preconditioned recipients of cadaveric kidneys, livers, hearts, 
and lungs who were given 3-5 x 10 8/kg adjuvant bone marrow at the 
same time as organ transplantation under standard FK 506-
prednisone treatment (Figure 5) (57). Chimerism estimated to be 
, 1000 x that occurring in conventional whole organ recipients 
~as reliably and safely produced and sustained. The persistent 
blood chimerism (usually >1%), trend toward donor specific 
nonreactivity, and high rate of patient and graft survival has 
marked these bone marrow augmented recipients as an advantaged 
~ohortK They are the first patients to undergo HLA-mismatched 
cadaver~c organ transplantation with the reasonable prospect of 
~ventually becoming drug free. The process of tolerance 
induction and drug wean~ng is expected to take 5 to 10 years in 
, , 
most patients who are given mismatched organs and in some the 
drug free state may never be attainable. 
With Bone Marrow 
With the discovery that whole organ transplantation caused 
spontaneous chimerism, it was realized that seemingly vast gap 
between the bone marrow and whole organ transplantation fields 
merely reflected entrenched differences of treatment strategy 
(Figure 6). The mutually censoring immunologic limbs were being 
left intact with organ transplantation, whereas the recipient 
limb was deliberately removed (cytoablationl in preparation. for 
bone marrow grafting procedures. It is doubtful that it is ever 
possible (much less desirable) with the cytoablation techniques 
of bone marrow transplantation to completely eliminate the entire 
recipient immune system. Although this was long assumed to have 
occurred in successful cases (Figure 1 B), a trace population of 
recipient leukocytes has been almost invariably detected with 
sensiti':e technlques in patients previously thought to have 
complete bone marrow replacement (58,59). These bone marrow 
recipients were in fact mirror images of successfully treated 
whole organ recipients, the difference being that their own 
rather than donor leukocytes constituted the trace populatlon. 
:n elther kind of recipient (whole organ or bone marrow), the 
appearance of MHC restricted ~eto and suppressor cells, enhancing 
antlbodies, and changes in cytokine profile could be construed as 
by-products of and accessory to the seminal event of mixed 
chimerism (Figure 1 C and D) . 
Beyond an adjuvant role for whole organ transplantation, an 
important question is whether HLA mismatched bone marrow without 
an accompanying organ can be engrafted in patients whose disease 
can be corrected with a minimal or even microchimeric state, 
using the same immunosuppression as for marrow-augmented kidney, 
liver, and heart recipients. The potential list of indications 
in which complete marrow replacement is unnecessary is a long 
0ne, exemplified by the lysozomal enzyme deficiencies (60). 
Another look into the future has been provided by the 
demonstration that xenograft transplantation is followed by the 
same cell migration process as that seen with allografts (61). 
EPISTEMOLOGY VERSUS DRY HISTORY 
~he legendary immunologist, Melvin Cohn (father of the 2-
slgnal concept :f self/non-self discrimination), wrote in 1994 
that "In its recent history, immunology has advanced largely by 
','01 ume [of publ ications 1 I complete with waste." (62), In Cohn 's 
opinion, the reason for the failure of more rapid conceptual 
advancement in his branch of science has been the preference of 
lmmunologists for small theories that explain one or onlv a few 
:acts articulated by Mitchison [63]) as opposed to the 
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development of generalized principles with which all facts could 
be explained (coherence of context). It would be hard to find a 
better way to illustrate the consequences of a small theory than 
those derivative from the durable one-way paradigm which was 
blindly accepted in spite of its failure to explain what was 
being seen daily in every transplantation clinic and laboratory. 
Virtually no hint of the two-way paradigm can be found in the 
literature before the description in June 1992 of microchimerism 
in organ recipients. If the spontaneous development of chimerism 
after organ transplantation had been known a third of a century 
ago, it would have been possible to correctly interpret 
observations in splenocyte and bone marrow transplant experiments 
reported by Simonsen (64,65) and Michie, Woodruff and Zeiss (66). 
The hypothesis of these earlier workers --- that acquired 
tolerance must ~esult from a 2-way (donor/recipient) immune 
~eaction --- resembled that later used to explain organ graft 
acceptance. Their great idea was abandoned because it could not 
be proved, delaYlng a true understanding of transplantation 
immunology for a third of a century. 
CONCLUSION 
Beacons of understanding shine forward as well as back. 
~omprehending the history of transplantation In terms of the two-
'.-Jay paradigm pro'ndes the intellectual means to devise better 
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treatment strategies, including the achievement of drug free 
tolerance, and ultimately the goal of xenotransplantation. 
lS 
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FIGURE LEGENDS 
Figure 1 (Upper panels) One-way paradigm in which 
transplantation is conceived as involving a unidirectional immune 
reaction: host-versus-graft (HVG) with whole organs (A) and 
graft-versus-host (GVH) with bone marrow or other lymphopoietic 
transplants (B). (Lower panels) Two-way paradigm with which 
transplantation is seen as a bidirectional and mutually 
cancelling immune reaction that is predominantly HVG with whole 
organ grafts (e), and predominantly GVH with bone marrow grafts 
and (D). 
Figure 2 Pattern of postoperative events with whole organ 
allograft acceptance, in the framework of the one-way paradigm. 
Figure 3 --- ~he pattern of convalescence after either organ or 
bone marrow ~ransplantation in the framework of the two-way 
paradigm. 
Figure 4 --- Explanation for the loss of an HLA matching effect 
',vi th whole organ transplantation. Rx: immunosuppress ion. 
Figure 5 --- Iatrogenic augmentation of the GVH component of the 
2-way paradigm by infusing 3-6 x 10 8 unaltered donor bone marrow 
cells at the same time as heart or other whole organ 
transplantation. When the recipient is llQt cytoablated, there is 
essentially no risk of GVHD. 
Figure 6 --- The growth as separate disciplines of bone marrow 
(right) and whole organ transplantation (left) from the seed 
planted by Peter Medawar during World War II. It was recognized 
in 1992 that these seemingly disparate disciplines were mirror 
images caused by different treatment strategies as explained in 
the text. GVBD, Graft versus host disease. 
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